Chi-Med Plans to Submit NDA for Surufatinib Following Pre-NDA Meeting with the U.S. FDA
01 juin 2020 02h00 HE
|
Hutchison China MediTech Limited
LONDON, June 01, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it has held its pre-New Drug Application (“NDA”) meeting with the U.S....
Chi-Med to Discuss Select Global Clinical Trial Data Presented at ASCO20
29 mai 2020 08h00 HE
|
Hutchison China MediTech Limited
― Savolitinib in MET exon 14 skipping NSCLC efficacy evaluable patients demonstrated 49.2% ORR, 93.4% DCR and 9.6 months DoR, including 36% patients with more aggressive disease subtype ― ―...
Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
29 mai 2020 02h00 HE
|
Hutchison China MediTech Limited
— First NDA filing of savolitinib globally — — Chi-Med seeking first-in-class Chinese marketing authorization for a selective MET inhibitor — LONDON, May 29, 2020 (GLOBE NEWSWIRE) -- Hutchison...
Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab
26 mai 2020 02h00 HE
|
Hutchison China MediTech Limited
– Collaboration to explore multiple solid tumor cancer indications – – Initial development focused on multi-cohort trials in the U.S., Europe, China and Australia – ...
Chi-Med Highlights Clinical Data to be Presented at the Upcoming ASCO20 Virtual Scientific Program
14 mai 2020 02h00 HE
|
Hutchison China MediTech Limited
LONDON, May 14, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of savolitinib,...
Chi-Med to Attend Upcoming Investor Conferences
08 mai 2020 04h12 HE
|
Hutchison China MediTech Limited
LONDON, May 08, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will participate...
Chi-Med Highlights Presentations of Surufatinib at the Upcoming AACR Virtual Annual Meetings
22 avr. 2020 04h00 HE
|
Hutchison China MediTech Limited
LONDON, April 22, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of surufatinib will be...
Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors
17 avr. 2020 02h00 HE
|
Hutchison China MediTech Limited
LONDON, April 17, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted two Fast...
Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Malignant Mesothelioma in China
31 mars 2020 02h45 HE
|
Hutchison China MediTech Limited
LONDON, March 31, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting...
Chi-Med Reports 2019 Full Year Results and Provides Updates on Key Clinical Programs
03 mars 2020 10h26 HE
|
Hutchison China MediTech Limited
Company to Host Annual Results Conference Call Today at 1:00 p.m. GMT / 8:00 a.m. EST / 9:00 p.m. HKT LONDON, March 03, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”)...